Cardio Diagnostics and FMS

FMS and Cardio Diagnostics Unite in ‘Heart Attack Prevention’ Initiative, Stock Soars

Cardio Diagnostics Holdings, a prominent player in the field of artificial intelligence-powered precision cardiovascular medicine tests, has joined forces with Family Medicine Specialists (FMS), a leading primary care provider based in Illinois boasting eight locations and a patient base numbering in the tens of thousands. The collaboration, announced today, will see FMS implement Cardio Diagnostics’ cutting-edge solutions aimed at identifying patients susceptible to coronary heart disease (CHD) events, including heart attacks. Following this announcement, the stock of Cardio Diagnostics Holdings experienced a surge of more than 60%.

At the time of this publication, Cardio Diagnostics Holdings Inc stock (CDIO) has witnessed a surge.
Cardio Diagnostics Holdings Inc
Current Price: $1.09
Change : +0.41
Change (%): (60.31%)
Volume: 80.8M
Source: Tomorrow Events Market Data

National statistics reveal heart disease as the foremost cause of mortality, a fact mirrored in Illinois where it accounts for a staggering 29% of all deaths. This initiative, aptly named the “Heart Attack Prevention” program, will harness the power of Cardio Diagnostics’ advanced blood-based epigenetic-genetic tests, known as Epi+Gen CHD, to stratify the risk levels of FMS’ patient population. According to the CDC, almost half of all Americans harbor at least one significant cardiovascular risk factor, be it diabetes, obesity, or hypertension. For many, the first indication of CHD comes in the form of a heart attack.

FMS will roll out Cardio Diagnostics’ heart attack risk assessment test in a cohort of at least 1,200 patients exhibiting CHD risk factors, covered by BlueCross BlueShield Medicare, Medicaid, HMO, and PPO health plans. By integrating Cardio Diagnostics’ technology, FMS clinicians will not only gain insight into their patients’ risks but will also be better equipped to tailor care plans to address these risks effectively. Ultimately, the initiative aims to stave off severe cardiac events and preempt avoidable treatment costs, which can escalate into the hundreds of thousands of dollars for heart attacks and their subsequent complications, such as heart failure.

Dr. Bellucci-Jackson, Owner and lead clinician at FMS, emphasized the commitment to preventing avoidable cardiac events, stating, “With over 10,000 patient visits monthly across our eight clinics, FMS is committed to preventing avoidable cardiac events in our patients.” He underscored the simplicity of Cardio Diagnostics’ tests, requiring only a blood draw, while highlighting the advanced insights they provide compared to current tools. Dr. Bellucci-Jackson also stressed the tangible benefits of proactive risk assessment in terms of both lives saved and substantial cost savings, considering the human and financial toll of unexpected heart attacks.

CEO and Co-Founder of Cardio Diagnostics, Meesha Dogan Ph.D., lauded FMS’s proactive approach, stating, “FMS’s proactive stance aligns with our mission. Our tests offer unparalleled, actionable molecular insights tailored to each patient, and this collaboration will enable the identification and management of at-risk patients to better prevent heart disease.” Dr. Dogan cited data from the Milken Institute, which estimates a return of $6.30 in savings for every $1 invested in preventive measures. This initiative, according to Dr. Dogan, exemplifies the broader shift in healthcare towards prevention and value-based care, ultimately yielding improved outcomes and reduced costs.

The joint effort between FMS and Cardio Diagnostics aims to mitigate the financial and human toll associated with undetected heart attack risk, benefiting both patients and healthcare providers while providing significant value to health plans. This initiative is poised to showcase the practical and cost-effective advantages of early heart attack risk detection and intervention. Looking ahead, the integration of value-based care and risk-bearing organizations in strategic partnerships with advanced diagnostic providers sets a blueprint for operationalizing value-based care objectives—a feat that many organizations have historically grappled with.

Related posts